This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rudek, M. A. Articles by Reed, E. Search for Related Content PubMed PubMed Citation Articles by Rudek, M. A. Articles by Reed, E. Social Bookmarking                            What's this?

Phase I Clinical Trial of Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer

From the Medicine Branch, Division of Clinical Sciences; Biostatistics and Data Management Section; Investigational Drug Branch, Cancer Therapy Evaluation Program; and Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Address reprint requests to William D. Figg, MD, National Cancer Institute, Building 10, Room 5A01, 9000 Rockville Pike, Bethesda, MD 20892; email wdfigg{at}helix.nih.gov

PURPOSE: This phase I clinical trial was designed to determine the maximum-tolerated dose and dose-limiting toxicities of the matrix metalloproteinase (MMP) inhibitor COL-3 in patients with refractory solid tumors.

PATIENTS AND METHODS: Thirty-five patients with different cancer types were enrolled. COL-3 doses were escalated from 36 mg/m²/d in successive cohorts of at least three patients. Circulating levels of MMP-2, MMP-9, vascular endothelial growth factor, and basic fibroblast growth factor were assessed during treatment. Pharmacokinetic parameters were assessed for single and multiple doses of drug.

RESULTS: Cutaneous phototoxicity was dose-limiting at 98 mg/m²/d. With the use of prophylactic sunblock, COL-3 was well tolerated at 70 mg/m²/d. The dose of 36 mg/m²/d was well tolerated without the use of sunblock. Other toxicities that did not seem to be related to dose or pharmacokinetics included anemia, anorexia, constipation, dizziness, elevated liver function test results, fever, headache, heartburn, nausea, vomiting, peripheral and central neurotoxicities, fatigue, and three cases of drug-induced lupus. Disease stabilization for periods of 26+ months, 8 months, and 6 months were seen in hemangioendothelioma, Sertoli-Leydig cell tumor, and fibrosarcoma, respectively. There was a potentially statistically significant relationship between changes in plasma MMP-2 levels and cumulative doses of drug when progressive disease patients were compared with those with stable disease or toxicity (P = .042).

CONCLUSION: COL-3 induced disease stabilization in several patients who had a nonepithelial type of malignancy. Phototoxicity was dose-limiting. We recommend the dose of 36 mg/m²/d for phase II trials.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. W Yeh, J.-P. Rougier, J.-W. Park, Q.-Y. Duh, M. Wong, Z. Werb, and O. H Clark Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A Endocr. Relat. Cancer, December 1, 2006; 13(4): 1173 - 1183. [Abstract] [Full Text] [PDF]

				L.-M. Postovit, E. A. Seftor, R. E.B. Seftor, and M. J.C. Hendrix Influence of the Microenvironment on Melanoma Cell Fate Determination and Phenotype Cancer Res., August 15, 2006; 66(16): 7833 - 7836. [Abstract] [Full Text] [PDF]

				S. S. Kocer, S. G. Walker, B. Zerler, L. M. Golub, and S. R. Simon Metalloproteinase Inhibitors, Nonantimicrobial Chemically Modified Tetracyclines, and Ilomastat Block Bacillus anthracis Lethal Factor Activity in Viable Cells Infect. Immun., November 1, 2005; 73(11): 7548 - 7557. [Abstract] [Full Text] [PDF]

				S. Syed, C. Takimoto, M. Hidalgo, J. Rizzo, J. G. Kuhn, L. A. Hammond, G. Schwartz, A. Tolcher, A. Patnaik, S. G. Eckhardt, et al. A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties Clin. Cancer Res., October 1, 2004; 10(19): 6512 - 6521. [Abstract] [Full Text] [PDF]

				W. R. Parulekar and E. A. Eisenhauer Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice J Natl Cancer Inst, July 7, 2004; 96(13): 990 - 997. [Abstract] [Full Text] [PDF]

				K. D. Miller, T. J. Saphner, D. M. Waterhouse, T.-T. Chen, A. Rush-Taylor, J. A. Sparano, A. C. Wolff, M. A. Cobleigh, S. Galbraith, and G. W. Sledge A Randomized Phase II Feasibility Trial of BMS-275291 in Patients with Early Stage Breast Cancer Clin. Cancer Res., March 15, 2004; 10(6): 1971 - 1975. [Abstract] [Full Text] [PDF]

				M. L. Wahl, T. L. Moser, and S. V. Pizzo Angiostatin and Anti-angiogenic Therapy in Human Disease Recent Prog. Horm. Res., January 1, 2004; 59(1): 73 - 104. [Abstract] [Full Text]

				M. M. Islam, C. D. Franco, D. W. Courtman, and M. P. Bendeck A Nonantibiotic Chemically Modified Tetracycline (CMT-3) Inhibits Intimal Thickening Am. J. Pathol., October 1, 2003; 163(4): 1557 - 1566. [Abstract] [Full Text] [PDF]

				M. A. Rudek, J. Venitz, Y. Ando, E. Reed, J. M. Pluda, and W. D. Figg Factors Involved in the Pharmacokinetics of COL-3, a Matrix Metalloproteinase Inhibitor, in Patients with Refractory Metastatic Cancer: Clinical and Experimental Studies J. Clin. Pharmacol., October 1, 2003; 43(10): 1124 - 1135. [Abstract] [Full Text] [PDF]

				A. C. Lockhart, R. D. Braun, D. Yu, J. R. Ross, M. W. Dewhirst, J. S. Humphrey, S. Thompson, K. M. Williams, B. Klitzman, F. Yuan, et al. Reduction of Wound Angiogenesis in Patients Treated with BMS-275291, a Broad Spectrum Matrix Metalloproteinase Inhibitor Clin. Cancer Res., February 1, 2003; 9(2): 586 - 593. [Abstract] [Full Text] [PDF]

				R. E. B. Seftor, E. A. Seftor, D. A. Kirschmann, and M. J. C. Hendrix Targeting the Tumor Microenvironment with Chemically Modified Tetracyclines: Inhibition of Laminin 5 {gamma}2 Chain Promigratory Fragments and Vasculogenic Mimicry Mol. Cancer Ther., November 1, 2002; 1(13): 1173 - 1179. [Abstract] [Full Text] [PDF]

				F. A. Scappaticci Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies J. Clin. Oncol., September 15, 2002; 20(18): 3906 - 3927. [Abstract] [Full Text] [PDF]

				Y. Liu, M. E. Ryan, H.-M. Lee, S. Simon, G. Tortora, C. Lauzon, M. K. Leung, and L. M. Golub A Chemically Modified Tetracycline (CMT-3) Is a New Antifungal Agent Antimicrob. Agents Chemother., May 1, 2002; 46(5): 1447 - 1454. [Abstract] [Full Text] [PDF]

				M. P. Bendeck, M. Conte, M. Zhang, N. Nili, B. H. Strauss, and S. M. Farwell Doxycycline Modulates Smooth Muscle Cell Growth, Migration, and Matrix Remodeling after Arterial Injury Am. J. Pathol., March 1, 2002; 160(3): 1089 - 1095. [Abstract] [Full Text] [PDF]

				M. Cianfrocca, T. P. Cooley, J. Y. Lee, M. A. Rudek, D. T. Scadden, L. Ratner, J. M. Pluda, W. D. Figg, S. E. Krown, and B. J. Dezube Matrix Metalloproteinase Inhibitor COL-3 in the Treatment of AIDS-Related Kaposi's Sarcoma: A Phase I AIDS Malignancy Consortium Study J. Clin. Oncol., January 1, 2002; 20(1): 153 - 159. [Abstract] [Full Text] [PDF]

				F. TOSETTI, N. FERRARI, S. DE FLORA, and A. ALBINI Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents FASEB J, January 1, 2002; 16(1): 2 - 14. [Abstract] [Full Text] [PDF]

				R. Hoekstra, F.A.L.M. Eskens, and J. Verweij Matrix Metalloproteinase Inhibitors: Current Developments and Future Perspectives Oncologist, October 1, 2001; 6(5): 415 - 427. [Abstract] [Full Text] [PDF]